Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 6 | 2026 | 61 | 1.500 |
Why?
|
| Community Pharmacy Services | 4 | 2020 | 25 | 1.410 |
Why?
|
| Puerto Rico | 17 | 2026 | 1413 | 1.210 |
Why?
|
| Cyclonic Storms | 3 | 2018 | 80 | 1.120 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2026 | 5 | 0.980 |
Why?
|
| Rheumatology | 1 | 2026 | 19 | 0.970 |
Why?
|
| Rheumatic Diseases | 1 | 2026 | 12 | 0.970 |
Why?
|
| Pharmaceutical Services | 1 | 2026 | 25 | 0.960 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2024 | 77 | 0.950 |
Why?
|
| Acute Coronary Syndrome | 3 | 2024 | 42 | 0.780 |
Why?
|
| Telemedicine | 1 | 2026 | 234 | 0.740 |
Why?
|
| Patient Care | 2 | 2019 | 31 | 0.730 |
Why?
|
| Disaster Planning | 2 | 2018 | 62 | 0.630 |
Why?
|
| Education, Pharmacy | 1 | 2019 | 57 | 0.560 |
Why?
|
| Thrombosis | 1 | 2018 | 81 | 0.550 |
Why?
|
| Health Services Accessibility | 4 | 2025 | 706 | 0.510 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 247 | 0.480 |
Why?
|
| Dietary Supplements | 1 | 2016 | 213 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 989 | 0.430 |
Why?
|
| Motivation | 1 | 2018 | 513 | 0.420 |
Why?
|
| Opioid-Related Disorders | 3 | 2021 | 195 | 0.410 |
Why?
|
| Humans | 25 | 2026 | 43102 | 0.380 |
Why?
|
| Smoking | 1 | 2018 | 1024 | 0.350 |
Why?
|
| Buprenorphine | 2 | 2021 | 51 | 0.330 |
Why?
|
| Male | 13 | 2026 | 23409 | 0.330 |
Why?
|
| Aryldialkylphosphatase | 3 | 2018 | 14 | 0.320 |
Why?
|
| Pharmacogenetics | 4 | 2024 | 67 | 0.300 |
Why?
|
| Middle Aged | 8 | 2026 | 12222 | 0.290 |
Why?
|
| Female | 13 | 2026 | 24698 | 0.290 |
Why?
|
| Ticlopidine | 2 | 2018 | 17 | 0.270 |
Why?
|
| Aged | 8 | 2025 | 8214 | 0.270 |
Why?
|
| Blood Platelets | 2 | 2018 | 81 | 0.260 |
Why?
|
| Cross-Sectional Studies | 6 | 2021 | 3156 | 0.260 |
Why?
|
| Vaccination | 2 | 2021 | 355 | 0.250 |
Why?
|
| Adult | 6 | 2026 | 13872 | 0.250 |
Why?
|
| Cross-Over Studies | 1 | 2026 | 115 | 0.240 |
Why?
|
| Ambulatory Care Facilities | 1 | 2026 | 68 | 0.240 |
Why?
|
| Prospective Studies | 3 | 2026 | 1600 | 0.230 |
Why?
|
| Genotype | 4 | 2024 | 800 | 0.230 |
Why?
|
| Patient Satisfaction | 1 | 2026 | 165 | 0.220 |
Why?
|
| Feasibility Studies | 1 | 2026 | 259 | 0.220 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 78 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 497 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 863 | 0.210 |
Why?
|
| Algorithms | 2 | 2024 | 509 | 0.210 |
Why?
|
| Benzodiazepines | 1 | 2023 | 21 | 0.200 |
Why?
|
| Drug Storage | 2 | 2020 | 28 | 0.180 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 34 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2018 | 206 | 0.170 |
Why?
|
| Guaifenesin | 1 | 2020 | 1 | 0.160 |
Why?
|
| Dextromethorphan | 1 | 2020 | 3 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2025 | 392 | 0.160 |
Why?
|
| Intention | 1 | 2021 | 108 | 0.160 |
Why?
|
| Dexamethasone | 1 | 2020 | 55 | 0.160 |
Why?
|
| Drug Compounding | 1 | 2020 | 93 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 156 | 0.150 |
Why?
|
| Professional Competence | 1 | 2019 | 42 | 0.150 |
Why?
|
| Caribbean Region | 3 | 2025 | 79 | 0.150 |
Why?
|
| Galactosyltransferases | 1 | 2018 | 6 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 36 | 0.150 |
Why?
|
| Platelet Aggregation | 1 | 2018 | 21 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 69 | 0.140 |
Why?
|
| Stents | 1 | 2018 | 67 | 0.140 |
Why?
|
| Community-Institutional Relations | 1 | 2020 | 219 | 0.140 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2018 | 58 | 0.140 |
Why?
|
| Telecommunications | 1 | 2018 | 1 | 0.140 |
Why?
|
| Electric Power Supplies | 1 | 2018 | 15 | 0.140 |
Why?
|
| Tetrazoles | 1 | 2018 | 46 | 0.140 |
Why?
|
| Professional Role | 1 | 2018 | 40 | 0.140 |
Why?
|
| Perception | 1 | 2019 | 215 | 0.130 |
Why?
|
| Prescription Drugs | 1 | 2018 | 32 | 0.130 |
Why?
|
| Pharmacies | 1 | 2018 | 23 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 231 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2017 | 96 | 0.130 |
Why?
|
| Disasters | 1 | 2018 | 79 | 0.120 |
Why?
|
| Food Supply | 1 | 2018 | 122 | 0.120 |
Why?
|
| Certification | 1 | 2016 | 21 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 432 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2017 | 174 | 0.110 |
Why?
|
| Health Education | 1 | 2017 | 363 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 5080 | 0.100 |
Why?
|
| Neoplasms | 1 | 2023 | 1377 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 749 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 252 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2024 | 863 | 0.070 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 7 | 0.070 |
Why?
|
| Latin America | 1 | 2025 | 55 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 2853 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1604 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2024 | 55 | 0.050 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 54 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 423 | 0.050 |
Why?
|
| Genomics | 1 | 2025 | 293 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2025 | 430 | 0.050 |
Why?
|
| Naloxone | 1 | 2021 | 56 | 0.040 |
Why?
|
| West Indies | 1 | 2021 | 13 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 734 | 0.040 |
Why?
|
| Dinucleoside Phosphates | 1 | 2020 | 11 | 0.040 |
Why?
|
| Expectorants | 1 | 2020 | 1 | 0.040 |
Why?
|
| Leadership | 1 | 2021 | 86 | 0.040 |
Why?
|
| Antitussive Agents | 1 | 2020 | 7 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 61 | 0.040 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.040 |
Why?
|
| Color | 1 | 2020 | 38 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 91 | 0.040 |
Why?
|
| Drug Stability | 1 | 2020 | 129 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 260 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 388 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 259 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2018 | 25 | 0.040 |
Why?
|
| Psychometrics | 1 | 2020 | 358 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 234 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 195 | 0.030 |
Why?
|
| Educational Status | 1 | 2019 | 339 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 236 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 278 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 317 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 440 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1857 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 370 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 760 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 972 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1009 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1234 | 0.020 |
Why?
|
| United States | 1 | 2020 | 5205 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3994 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 6081 | 0.010 |
Why?
|